Journal Abstract Detail

ORIGINAL ARTICLE: K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Date: 10/22/2008
Journal Name: New England Journal of Medicine
Author: New England Journal of Medicine

This study examined the mutation status of the K-ras gene in colorectal tumors from patients who were enrolled in a trial of cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR). A survival benefit was found among patients with tumors bearing wild-type K-ras but not among patients with tumors bearing mutated K-ras. Wild-type K-ras is essential in transmitting signals initiated by EGFR.

URL: http://content.nejm.org/cgi/content/short/359/17/1757?rss=1&query=current